Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Heterologous Prime-boost COVID-19 Vaccine Schedule (AZD1222 and MVC-COV1901)
NCT05054621Phase 2Completed
- Sponsor
- Chang Gung Memorial Hospital
- Start
- Sep 2021
- Primary completion
- Aug 2022
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of MVC-COV1901 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Chang Gung Memorial Hospital. Primary endpoint: Neutralizing antibody against SARS-CoV-2 at Day 28. Started Sep 2021; status: completed.
02
Drugs
MVC-COV1901
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05054621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05054621.